MedTrace Logo

The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients

NCT04452929 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2020-10-08

No results posted yet for this study

Summary

A randomized, double-blind, placebo-controlled, parallel study to investigate the effect of erenumab in calcitonin-gene related peptide and cilostazol experimental models of migraine in humans. Followed by a 6-month open-label extension.

Conditions

  • Migraine
  • Migraine Without Aura
  • Migraine With Aura

Interventions

DRUG

Erenumab

Subcutaneous injection of 140 mg erenumab.

DRUG

Placebo

Subcutaneous injection of saline placebo.

DRUG

Calcitonin gene-related peptide

Intravenous infusion of 1.5ug/min calcitonin gene-related peptide over 20 minutes.

DRUG

Cilostazol

Oral intake of 200 mg cilostazol.

Sponsors & Collaborators

Principal Investigators

  • Thien P Do, MD · Danish Headache Center

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-22
Primary Completion
2022-02-28
Completion
2022-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04452929 on ClinicalTrials.gov